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InﬂammationLipin-1 deﬁciency is associated with massive rhabdomyolysis episodes in humans, precipitated by febrile ill-
nesses. Despite well-known roles of lipin-1 in lipid biosynthesis and transcriptional regulation, the pathogenic
mechanisms leading to rhabdomyolysis remain unknown. Here we show that primary myoblasts from lipin-1-
deﬁcient patients exhibit a dramatic decrease in LPIN1 expression and phosphatidic acid phosphatase 1 activity,
and a signiﬁcant accumulation of lipid droplets (LD). The expression levels of LPIN1-target genes [peroxisome
proliferator-activated receptors delta and alpha (PPARδ, PPARα), peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α), acyl-coenzyme A dehydrogenase, very long (ACADVL), carnitine
palmitoyltransferase IB and 2 (CPT1B and CPT2)] were not affected while lipin-2 protein level, a closely related
member of the family, was increased. Microarray analysis of patients' myotubes identiﬁed 19 down-regulated
and 51 up-regulated genes, indicating pleiotropic effects of lipin-1 deﬁciency. Special attention was paid to the
up-regulated ACACB (acetyl-CoA carboxylase beta), a key enzyme in the fatty acid synthesis/oxidation balance.
We demonstrated that overexpression of ACACB was associated with free fatty acid accumulation in patients'
myoblasts whereas malonyl-carnitine (as a measure of malonyl-CoA) and CPT1 activity were in the normal
range in basal conditions accordingly to the normal daily activity reported by the patients. Remarkably ACACB
invalidation in patients' myoblasts decreased LD number and size while LPIN1 invalidation in controls induced
LD accumulation. Further, pro-inﬂammatory treatments tumor necrosis factor alpha + Interleukin-
1beta(TNF1α + IL-1ß) designed to mimic febrile illness, resulted in increased malonyl-carnitine levels, reduced
CPT1 activity and enhanced LD accumulation, a phenomenon reversed by dexamethasone and TNFα or IL-1ß in-
hibitors. Our data suggest that the pathogenic mechanism of rhabdomyolysis in lipin-1-deﬁcient patients com-
bines the predisposing constitutive impairment of lipid metabolism and its exacerbation by pro-inﬂammatory
cytokines.
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Lipin-1 deﬁciency is a major cause of severe myoglobinuria in early
childhood [1,2]. Despite well-known physiological roles of lipin-1 in
lipid biosynthesis and transcriptional regulation in the adipocyte and
liver, the pathogenic mechanisms leading to muscle lysis still remain
to be elucidated. The few reports have been published for this disease
in humans, are mainly limited to the clinical and genetic description of
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dephosphorylates phosphatidic acid (PA) to diacylglycerol (DAG), a
common precursor for triglycerides (TAG) and phospholipids (PL)
synthesis [3–5]. It also has transcriptional coregulator activity which,
through association with PPARα, PGC-1α, SREBP1 or NFATc4, regulates
lipid metabolism and mitochondrial respiratory chain (mRC) [6–10].
Lipin-1 is most abundant in adipocytes, skeletal muscle ﬁbers,
liver [11] and myocardium [7], and is subject to regulation by
phosphorylation/dephosphorylation by mTOR. The mammalian family
of lipins includes two other closely related members, lipin-2 and lipin-
3, encoded by distinct genes and sharing 44-48% overall identity with
high homology in their C-terminal moiety (C-LIP domain). Motifs for
PAP1 activity (DXDXT) and interaction with transcriptional factors
(LXXIL) are conserved, and the three lipins exhibit PAP1 activity and
can complement each other when coexpressed [11–13]. PAP1 activity
can modulate circulating TAG and fatty acid (FA) levels in mouse and,
in this respect, fatty acid oxidation (FAO) appears correlated to efﬁcient
storage of FA in TAG [14]. As awhole, the dual function of lipin-1 confers
this protein a unique pivotal role in FA metabolism, oxidative
phosphorylation and lipid-dependent energy metabolism.
Evidence for transcriptional activity of lipin-1 in the liver and
adipocytes was obtained by gene expression studies documenting
lipin-1 binding to PPARα and PGC-1 and subsequent regulation of
genes encoding FAO enzymes and PPARα itself [9,15,16]. Accordingly,
lipin-1-deﬁcient mice (ﬂd) exhibit reduced expression of PPAR-
regulated genes and impaired FAO activity [17]. These mice display
signs of lipodystrophy and poor adipocyte differentiation. Reciprocally,
overexpression of PPARγ in ﬂd mouse pre-adipocytes rescues their
ability to differentiate [18]. Finally, overexpression of lipin-1 in the
skeletal muscle of transgenic mice dramatically affects energy balance
[19] and modulation of FA metabolism in the heart alters lipin-1
response [7]. Interestingly, the mitochondria from Drosophila deleted
for the lipin-1 ortholog have altered morphology [4] and human
patients accumulate lipid droplets in the skeletal muscles along with
occasional ragged-red ﬁbers [20]. Therefore, lipin-1 might regulate
energetic pathways towards oxidative metabolism and lipid utilization
[21]. In humans, episodes of myoglobinuria are mostly precipitated by
febrile illnesses [20], suggesting a critical role of inﬂammatory stress
response.
Here we study for the ﬁrst time the consequences of lipin-1
deﬁciency in human myoblasts and myotubes, and show that it
alters lipid metabolism at least in part, through the up-regulation
of the gene encoding acetyl-CoA carboxylase 2 (ACC2), a key
enzyme in the fatty acid synthesis/FAO balance. On this basis we
propose a physiopathological mechanism for acute rhabdomyolysis
episodes, associating genetic and environmental components.
2. Materials and methods
2.1. Human subjects
Experiments were conducted on the skeletal muscle, myoblasts and
myotubes obtained from 3 patients carrying two recessively-inherited
mutations in LPIN1 gene and 3 age and sex-matched controls. This
work has been approved by our institutional ethical committee
after declaration to the Département de la Recherche Clinique et du
Développement and informed consent was obtained from the parents.
The 3 patients were previously described [1]: P1, a boy aged 8 years old
(p.Asp316LeufsX26 and p.Glu766_Ser838del), P2, a girl aged 3 years old
(p.Ser315X and p.Arg388X), and P3, a girl aged 10 years old
(p.Asn417LysfsX22 and p.Glu766_Ser838del).
2.2. Muscle biopsies and primary human myoblasts and myotubes
Human primary myoblasts were isolated and grown as described
[22]. CD56+ myoblasts were isolated by ﬂow cytometry cell sortingusing an anti CD56-APC conjugated antibody (Biosciences ref. 555518).
Myotubeswere derived fromconﬂuentmyoblast cultures after replacing
HamF10 medium by DMEM supplemented with 1% horse serum,
100 μg/mL human apotransferrine, 10 μg/mL insulin, and myotubes
were used after 10 days of differentiation. Myoblasts were subjected to
various stress conditions to mimic those believed to trigger episodes of
rhabdomyolysis, such as pro-inﬂammatory cytokines (TNFα, IL-1ß,
R&D Systems) and poly(I:C) a synthetic inducer of the antiviral response,
alone or combined and for various periods of time. The two following
pro-inﬂammatory conditions were retained for further investigations
i.e. the association of TNFα and IL-1ß (10 ng/mL each), and poly(I:C)
(25 μg/mL, Invivogen). 50% conﬂuent cell cultures were synchronized
by 12 h serum starvation before being submitted to the stress in regular
HamF10 medium for the indicated times. Cells were trypsinized and
immediately used or stored at −80 °C before being processed. All
experiments were repeated at least three times. The efﬁcacy of pro-
inﬂammatory stimulations was conﬁrmed by measuring IL6 release in
culture medium with an immunoradiometric assay kit (Immunotopics)
as previously described [23]. Cytokine inhibitors anakinra (antagonist
of IL-1β receptor, 1 μg/mL) and ab9635 (anti TNFα antibody, 1 μg/mL,
abcam), or the synthetic glucocorticoid dexamethasone (0.2 μM, Dex,
Sigma), were further added in the culture medium respectively 1 h or
12 h prior to the 24 h-incubation with TNFα + IL-1β.2.3. Oil red O staining
Cells were washed 5 times with PBS buffer then ﬁxed in Baker's
ﬁxative for 30 min and rinsedwithwater. Prior to use, Oil red O solution
(Sigma-Aldrich) aggregates were eliminated by ﬁltration on 0.22 μm
membrane. The number of cells displaying small, large and aggregated
LDs were counted in at least 4 randomly selected ﬁelds. LD aggregates
were deﬁned as intensely stained areas of irregular shape evocative of
juxtaposed LDs.2.4. Gene expression studies
2.4.1. Real-time quantitative RT-PCR
Total RNA was extracted from skeletal muscle samples, myoblasts
and myotubes using the Trizol reagent (Invitrogen) and RNeasy Mini
Kit (Qiagen). Single-stranded cDNA was synthesized from 2 μg of total
RNA using the High Capacity RNA-to-cDNA Kit (Applied biosystems).
Real-time quantitative reverse transcription PCR (qPCR)was performed
using an ABI PRISM 7300 Sequence Detection System instrument and
TaqMan Universal PCR Master Mix (Applied Biosystems). Reactions
were performed in triplicate using commercially available Taqman kits
(Applied Biosystems). Target gene expression was normalized to
POLR2A mRNA level.2.4.2. Affymetrix microarray study
DNA microarray analyses using Affymetrix Human Genome
chips HG-U133plus2.0 were performed on myotubes from the
three patients and the three controls with or without TNFα plus
IL-1ß stimulation for 24 h. Total RNA was extracted and used for
genome-wide transcription analysis. Data analysis was performed
using Affymetrix Microarray Suite 5.0 software to generate an
absolute analysis for each chip. Each chip was scaled globally to a
target intensity value of 800 to allow for inter-array comparisons.
All image ﬁles and cell intensity ﬁles corresponding to each
expression proﬁle are available (the microarray data related to
this paper have been submitted to the Array Express data reposito-
ry at the European Bioinformatics Institute (http://www.ebi.ac.uk/
arrayexpress/) under the accession number: Username: Review-
er_E-MEXP-3761; Password: iysugop4r).
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Myoblast proteins were obtained after lysis in ice-cold RIPA buffer
supplemented with a cocktail of protease inhibitors (Sigma-Aldrich)
according to standard protocols. Primary antibodies (Lipin-1 (RD,
AF3885), lipin-2 (Santa Cruz, sc-134433), ACACB (Cell signal Technology,
3662) [24], Malonyldecarboxylase (abcdm, ab95945) and β-Actin (Santa
cruz, sc-81178)) were detected by appropriate HRP-conjugated
secondary antibody followed by ECL detection.
2.6. Biochemical investigations
2.6.1. PA phosphatase activity
PA phosphatase activity was measured at 37 °C for 20 min as
previously described [5]. Total PAP activity wasmeasured in the presence
of 1 mMMgCl2. PAP2 activity (Mg2+-independent) wasmeasured in the
same conditions except that MgCl2 was chelated by 2 mM EDTA. The
Mg2+-dependent PAP1 activity was calculated by subtracting PAP2
activity from total enzyme activity. One unit of PAP activity was deﬁned
as the amount of enzyme that catalyzed the formation of 1 nmol of
product/min. Speciﬁc activity was deﬁned as units/mg protein.
2.6.2. Total free fatty acid (FFA), phospholipid and triacylglycerol content
Total free fatty acid (FFA), phospholipid and triacylglycerol content
were analyzed by gas chromatography as previously described [25].
Lipids were ﬁrst separated by thin layer chromatography and the silica
matrix zones corresponding to total FFA, PL and TAG were scrapped
from the plate and quantiﬁed by GC-ﬂame ionization detector.
2.6.3. Carnitine palmitoyltransferase I (CPT1) activity and malonyl-carnitine
Carnitine palmitoyltransferase I (CPT1) activity andmalonyl-carnitine
content were determined as described [26]. The assay was based on the
production of deuterated [D5]-acylcarnitines by intact cells incubated
with deuterated palmitate ([16-2H3, 15-2H2]–[D5]-palmitate) and
excess of L-carnitine. CPT1 activity was assessed by initial rates of
acylcarnitines over the ﬁrst 6 min of incubation thus taking into account
the potential catabolism of D5-palmitate through FAO. Acylcarnitines
were analyzed by ESI/MS–MS [26,27]. Speciﬁcity of ESI/MS–MS analysis
was obtained through selection of compounds generating the m/z 85
ion, the molecular weight of selected compounds further identifying the
acylcarnitine. Malonyl-carnitine sample content was determined by
the ratio between butylated malonyl-carnitine and its internal standard
(i.e. butylated deuterated propionyl-carnitine). Myoblasts (106 cells/mL)
were incubated in the buffers used for CPT1 assays on whole blood [27].
Myoblast pellets were resuspended in the buffer used for respiration
measurements [28] without inclusion of malate.
2.6.4. Fatty acid oxidation
Fatty acid oxidationwasmeasured inpatients' and controls'myoblasts
by the quantiﬁcation of 3[H]-H2O production from (9,10-3H)-palmitate as
previously described [22]. The oxidation rates were expressed as
nanomoles of 3H fatty acid oxidized/h/mg of protein.
2.6.5. ATP levels
ATP levels were determined with the bioluminescence assay kit HSII
(Roche Applied Science, Indianapolis, IN, USA) according to the manu-
facturer's instruction. Cells seeded in triplicate were washed in warm
PBS. Lysates were combined with luciferase and the resulting light
emission was quantiﬁed by a microplate-format luminometer. Proteins
were also quantiﬁed using the Bradford kit (Sigma) and the values of
luminescence were corrected to the protein level.
2.7. Endoplasmic reticulum (ER) stress
ER stress was evaluated by studying the expression of several target
genes of the ER stress response by PCR such as BIP, HERP, GRP94, andEDEM, or the integrated stress response such as ASNS, GADD34, ATF3,
and CHOP.
2.8. siRNA transfections
Myoblasts were transfected using the jetPRIME® transfection
reagent (polyplus) according to the supplier's recommendations,
with 25 nM siRNA of mission esiRNA ACB (EHU 138011, Sigma)
targeting human ACACB, or siRNA targeting human LPIN1
(siGenome duplex # 2, D-017427-0 Dharmacon). The non
targeting siRNA #2 (Dharmacon) was used as negative control.
All experiments were performed in triplicate.
2.9. Cell cycle analysis
Myoblasts cultured with or without TNFα plus IL-1ß (10 ng/mL
each) were collected, ﬁxed in 70% ethanol 1 h at 4 °C and stained with
40 μg/mL of propidium iodide and 100 ug/mL of RNAse. Samples were
analyzed by ﬂow cytometry at 488 nmexcitation and 630 nmemission.
2.10. Statistical analysis
Gene expression and biochemical datawere expressed asmean ± SD
or SEM as indicated. Differences between control and deﬁcient cells were
analyzed by one-way analysis of variance and Student's t test.
3. Results
3.1. LPIN1 mutations result in reduced LPIN1 mRNA, protein and enzyme
activity
We determined LPIN1 gene expression and protein levels in isolated
primary myoblasts derived from 3 patients and 3 age and sex-matched
controls (Fig. 1). LPIN1 mRNA was reduced about 3 fold in patients'
myoblasts comparedwith controls (Fig. 1B). Themutated lipin-1 proteins
were truncated before the site of antibody recognition (residues 448–574,
Fig. 1A) and could not be detected by immunoblotting analysis (Fig. 1C).
Surprisingly lipin-1 was not detectable in patients P1 and P3 carrying
the p.Glu766_Ser838del LPIN1 allele generating an in-frame truncation
in the C-LIP domain suggesting that the protein resulting from this
frequent mutation is unstable. Compared with control myoblasts, a
protein with a slightly higher molecular weight was detected in a control
skeletal muscle sample (Fig. 1C) which may reﬂect different degrees of
post-translational modiﬁcations of lipin-1 between muscle tissue and
cultured myoblasts as lipin-1 is known to be subjected to SUMOylation
and multiple phosphorylation [12,28]. Accordingly, PAP1 activity was
dramatically decreased in patients' myoblasts although not totally
abolished whereas PAP2 activity (i.e. the Mg2+-independent activity)
remained unchanged compared with controls (Fig. 1D).
3.2. Lipin-2 is up-regulated in lipin-1-deﬁcient myoblasts
Because lipin family proteins share large sequence identity and
exhibit similar activities, lipin-2 and lipin-3 proteins were studied.
Unexpectedly, lipin-2 protein was speciﬁcally induced in the mutated
cells while it was barely detectable in control myoblasts and muscle
(Fig. 1C). However, lipin-2 mRNA levels were not signiﬁcantly elevated
in patient cells as indicated by the transcriptomic study suggesting that
post-transcriptional mechanisms underlie lipin-2 up-regulation in the
patients. Lipin-3 protein could not be detected in both patients and
control myoblasts.
3.3. Lipid droplet content is increased in patients' myoblasts
Oil red O staining showed the presence of LDs in the cytoplasm of
17% ± 2% of the controls' myoblasts in basal condition which essentially
Fig. 1. Lipin-1 expression and activity. A: Schematic representation of Lipin-1 protein showing the mutations of each patient. The region deleted by the in-frame C-terminal deletion of
patients P1 and P3 is shown by the thick black bar. The region recognized by the antibody AF3885 is indicated by vertical arrows. NLS: nuclear localisation signal, PAP: catalytic site for
PAP1 activity, Coactivator: transcriptional coactivator binding motif. B: LPIN1 mRNA expression in basal culture conditions measured by real-time RT-PCR and normalized by POLR2A
expression. C: Immunoblot analysis of lipin-1 and lipin-2 expression inmyoblasts in basal conditions. P: Patients, C: Controls, Sm: skeletal muscle. D: PAP1 and PAP2 activity inmyoblasts.
from controls (C) and patients (P) grown in basal conditions. Results are shown as mean ± SD from three independent experiments.
Fig. 2. Representative histological oil red O staining of myoblasts from controls (left panels, C1, C2) and patients (right panels, P1, P2 and P3). LDs appear as red circular vacuoles in the
cytoplasm. Numbers in parentheses indicate the percentage of LD positive cells.
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Fig. 3. Lipid analysis inmyoblasts. A: Lipids from 3.106 myoblasts from lipin-1-deﬁcient patient (P1) and control (C1) grown in basal condition were extracted and analyzed by thin layer
chromatography. Results are from three independent experiments. Hela cells extract, essentially devoid of free fatty acids are used as a control for lipid extraction. B: Quantiﬁcation of TAG
and FFA relative to PL content. C: Comparison of TAG and PL contents (μg) in myoblasts treated or not with TNFα + IL-1ß. D: Comparison of the TAG content relative to PL content in
myoblasts treated or not with TNFα + IL-1ß. Results are presented as mean ± SD.
Table 1
Phospholipid and triacylglyceride (TAG) contents in myoblasts of lipin-1-deﬁcient patients
and controls grown in basal and pro-inﬂammatory stress conditions (TNFα + IL-1β).
Stress increases triacylglycerides content. P: patients, C: control. Data are expressed as
mean ± SD (n = 3), *: p b 0.05 compared to respective basal condition.
Sample Stimulation Phospholipids (μg) Triacylglycerols (μg) % TAG
P1 Basal 28.31 ± 1.30 1.89 ± 0.07 6.67
TNFα + IL-1β 31.07 ± 2.77 5.40 ± 0.60 17.38*
P2 Basal 34.81 ± 0.30 2.15 ± 0.27 6.17
TNFα + IL-1β 34.76 ± 1.25 3.30 ± 0.08 9.49*
C1 Basal 31.58 ± 3.64 1.42 ± 0.14 4.50
TNFα + IL-1β 27.47 ± 0.62 2.63 ± 0.07 9.57*
Stress increases TAG content. Phospholipid and triacylglycerol contents in myoblasts of
lipin-1-deﬁcient patients and controls grown in basal and pro-inﬂammatory stress
conditions (TNFα + IL-1β). P: Patients, C: Control. Data are expressed as mean ± SD
(n = 3), *: p b 0.05.
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myoblasts showed an accumulation of LDs (77 ± 10%, 95 ± 5% and
72.5 ± 7% for P1, P2 and P3 respectively), which mostly composed of
large LDs.
Free fatty acid (FFA) content was dramatically increased in patients'
myoblasts compared to controls while total phospholipids and TAG
contents were not signiﬁcantly modiﬁed (Fig. 3A and B, Table 1). No
signiﬁcant change was detected in FA composition, as well as in the
length and level of unsaturation of acyl chains in phosphatidic acid
and phospholipids.
3.4. The expression of known lipin-1 regulated genes involved in energy
metabolism is not altered by lipin-1 deﬁciency
Quantitative real-time PCR analysis showed that basal expression
levels of genes such as PPARδ, PPARα, and PGC-1α, described as lipin-1-
transcriptionally modulated genes in the liver and adipocytes, and
genes encoding enzymes of energetic pathways, like ACADVL (VLCAD),
CPT1b and CPT2 [9,15,16] were not signiﬁcantly different between
patients' and controls' myoblasts (Table 2).
3.5. Lipin-1 deﬁciency is not associated with ER stress
Because disturbance of ER homeostasis, suggested by the increased
formation of LDs, contributes to metabolic dysfunction, we assessed
by RT-PCR the expression of genes induced during ER stress response
such as BIP, HERP, GRP94, and EDEM, ormarkers of the integrated stress
response such as ASNS, GADD34, ATF3, and CHOP [29]. Comparison of
myoblasts from two patients and one control failed to identify a speciﬁc
pattern in lipin-1-deﬁcient cells (data not shown), suggesting that ER
stress is not a common feature in this pathology. Furthermore, neither
altered nuclear or ER morphology nor membrane remodeling wasobserved by electronic microscopy in the myoblasts of any patients
whereas it conﬁrmed the constitutive presence of LDs in lipin-1-deﬁ-
cient myoblasts (data not shown).
3.6. Lipin-1 deﬁciency up-regulates ACACB in bothmyotubes andmyoblasts
In order to identify genes modulated (directly or indirectly) by
lipin-1 deﬁciency we conducted microarray experiments using
myotubes derived from 3 patients and 3 controls (Fig. S1A).
Applying a two-fold selection ﬁlter we identiﬁed 19 down-
regulated and 51 up-regulated genes in lipin-1-deﬁcient myotubes
maintained in basal medium (Fig. S1B, Tables S1 and S2). Down-
regulated genes included LPIN1 (4 fold), PPAP2B encoding one of
the enzymes with PAP2 activity and several members of the HOXC
Table 2
Genes differentially expressed in myoblasts from patients and controls in basal culture
condition. Results are presented as mean ± SD. No signiﬁcant difference was observed
between patients and controls.
Controls Patients
PPARα 0.0523 ± 0.0019 0.0600 ± 0.0129
PPARδ 0.8406 ± 0.0750 0.8051 ± 0.1400
PGC-1α 0.0008 ± 0.0005 0.0006 ± 0.0003
ACADVL 0,1020 ± 0.0081 0.0817 ± 0.0175
CPT1b 0.0214 ± 0.0127 0.0262 ± 0.0084
CPT2 0.7355 ± 0.2724 0.6070 ± 0.0596
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HOXA cluster, CAPN6, HOPX (7 fold) involved in cardiomyocyte
development, PIPOX (8 fold), CXCR4 (13 fold), CXCL13 (19 fold)
and ACACB (2–3 fold). Microarray study conﬁrmed that none of
the genes previously reported as modulated by lipin-1 in the liver
and adipocytes were detected [7,8,30]. The expression of some of
these target genes was further measured by qPCR conﬁrming it
was unchanged despite lipin-1 deﬁciency. Interestingly, ACACB
expression, encoding acetyl-CoA carboxylase (ACC) beta (or
ACC2), the main ACC isoform in skeletal muscle was increased.
This enzyme catalyzes the carboxylation of acetyl-CoA to generate
malonyl-CoA, the rate-limiting step in fatty acid synthesis [31].
Because of this role, the up-regulation of this gene in the patients'
myotubes was further studied. ACACB up-regulation was directly
conﬁrmed in the patients' myotubes by real-time PCR (Fig. 4A)
and protein immunoblotting (Fig. 4B).Fig. 4. Analysis of ACACB expression and activity and CPT1 activity inmyoblasts. A: mRNA level
patients (P) measures are shown. *: p b 0.01 P3 vs respective C; ◊: p b 0.01 C basal vs TNFα +
myoblasts. Results are presented as mean ± SD. *: p b 0.001 C(TNFα + IL-1ß) vs P (TNFα +
palmitoylcarnitine production bymyoblasts incubatedwith deuterated palmitate. Eachbar repr
from one patient and one control.3.7. MalonylCoA content is not changed by ACACB up-regulation
ACACB activitywas indirectly assessed inmyoblasts frompatients and
their cognate controls by the measure of malonyl-carnitine which under
excess L-carnitine reﬂects malonyl-CoA concentration. In basal culture
conditions malonyl-carnitine content was not signiﬁcantly changed
in any patient and appeared comparable to its control (Fig. 4C showing
the data of patient 3 and its control: 40.63 ± 7.37, control 26.62 ±
4.83 pmol/mg protein, p = 0.187; data of patients 1 and 2, performed
only once due to limited availability of primary myoblasts are similar
(not shown). ACC phosphorylation, known to inhibit its carboxylase
activity, was not modiﬁed in lipin-1-deﬁcient patients (data not
shown). However the strong cross-reaction of the antibody with
phosphorylated ACC1, due to the complete identity with ACC2 in this
region did not allow us to distinguish the level of phospho-Ser179 ACC2.
ACACA and ACACB encode the cytosolic (ACC1) and mitochondrial
(ACC2) acetyl-CoA carboxylase isoforms, respectively. In contrast to
ACC1 which directly contributes to FA synthesis, mitochondrial ACC2-
driven malonyl-CoA production plays a major role in the regulation of
mitochondrial FAO by inhibiting CPT1 activity, the rate-limiting step in
mitochondrial FAO. Deuterated acylcarnitine production was measured
as an index of CPT1 enzymatic activity (Fig. 4D). It was changed only in
patient's 1 cells compared to its control 1, and not in patients' 2 and 3
cells compared to their controls. In agreementwith the previous results,
FAO ﬂux in P3 myoblasts was also comparable to controls (data not
shown).
However, a signiﬁcant ~15% reduction of ATP content was measured
in the myoblasts from two patients suggesting an impairment of the
energetic metabolism in some patients (Fig. S2).of ACACBmeasured by real-time RT-PCR inmyotubes. The mean ± SD of controls (C) and
IL-1ß. B: Immunoblotting of ACACB protein in myotubes, C: malonyl-carnitine content in
IL-1ß). D: CPT1 activity in myoblasts. CPT1 was assayed by initial rates of deuterated
esents themean value of two separate determinations obtainedwithmyoblasts originating
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Lipin-1 siRNA transfection of control myoblasts (Fig. 5A) reduced
lipin-1 expression to levels similar to patient's cells (Fig. 5A and B).
Remarkably, it induced an accumulation of LDs relatively to off-target
(control) siRNA (Fig. 5C, G and H). Reciprocally, reduction of ACACB
expression in patient's myoblasts to levels similar to controls (Fig. 5D
and E) decreased LD number and size compared to off-target siRNA
(Fig. 5F, G and H) conﬁrming the link between LDs, lipin-1 deﬁciency
and ACACB overexpression. In addition, CPT1 activity was increased in
patients' cells transfected with siRNA ACACB (Fig. 5I) further supporting
the inverse relationship between ACACB overexpression and alteration
of lipid metabolism.
3.9. Pro-inﬂammatory cytokines enhance lipidmetabolism defect in human
lipin-1-deﬁcient myoblasts
Myoblasts were then submitted to two paradigms of pro-
inﬂammatory stress, poly(I:C) treatment (25 μg/mL, mimicking
viral infection) and a combination of TNFα and IL-1β (10 ng/mL
each), expecting to elicit an inﬂammatory stress and partially
mimic conditions potentially triggering the acute metabolic
decompensations in the patients. As expected, myoblasts from
the patients and controls responded to pro-inﬂammatory stress
by a robust IL6 secretion (Fig. 6A) reaching its maximum aroundFig. 5. Lipin-1 and ACACB expression, regulatemalonyl-carnitine content, CPT1 activity and LD a
1 siRNA and patient's myoblasts with the same ct siRNA or ACACB siRNA as indicated. A: mRNA
the bottom (C: control P3, patient 3), B: Lipin-1 protein expression, C: oil redO staining of C3my
red O staining of P3myoblasts (magniﬁcation 20x), G: percentage of cells showing LD accumula
fection (gray bars) expressed in % of activity in appropriate control myoblasts. Results are pres10 h after TNFα + IL-1ß stimulation and between 3 and 6 h post
stimulation with poly(I:C) (not shown). The response was much
stronger in TNFα + IL-1ß-stimulated myoblasts (mean 200–
300,000 pg/mL) compared to poly(I:C) (mean 2–4000 pg/mL)
indicating that poly(I:C) induced a weaker inﬂammatory response.
IL6 release reached similar levels in control and lipin-1-deﬁcient
cells under each treatment (Fig. 6A).
Cell proliferation was analyzed by cell cycle phase distribution of
cells at G2/M by ﬂow cytometry. Cell cycle distribution was analyzed
at 24 h. In basal condition control's and patient's cells in G2M were
25.5% and 21.2 respectively. No signiﬁcant difference was observed
after 24 h of TNFα + IL-1β stimulation compared to basal values.
3.9.1. LPIN1 mRNA expression and activity
TNFα + IL-1ß treatment resulted in a prolonged two-fold down-
regulation of LPIN1 mRNA expression in the patients and control
myoblasts (Fig. 6B), while poly(I:C) treatment led to a transient two-
fold decrease in the patients' cells which appeared milder in controls
and returned to basal levels after 24 h of treatment (data not shown).
PAP1 and PAP2 activities were unchanged by inﬂammation conditions
in patients' and controls' myoblasts except for myoblasts from patient
P2 which displayed a moderate PAP2 activity increase after inﬂam-
matory stress (Fig. 6C). Lipin-1 protein level was unaffected by inﬂam-
matory condition in the control's myoblasts (not shown) suggesting
that lipin-1 protein has a relatively long half-life. TNFα + IL-1βccumulation. Control's myoblasts were transfectedwith either of target siRNA (ct) or lipin-
level measured by real-time RT-PCR inmyotubes. The name of the samples is indicated at
oblasts (magniﬁcation 20x), D: ACACBmRNA expression, E: ACC2protein expression, F: oil
tion, H: distribution of LDs according to their size, I: CPT1 activity after ACACB siRNA trans-
ented as mean ± SD excepted for panels H and I.
Fig. 6. Inﬂammatory stress response. A: representative IL6 secretion from controls and patients after TNFα + IL-1β (left) or poly(I:C) (right) treatment. B: Time course analysis of lipin-1
mRNA expression under TNFα + IL-1β stimulation. Results are represented as fold variation over basal level. C: PAP activity after TNFα + IL-1β and poly(I:C) stimulation. D: LPIN2mRNA
expression measured by real-time RT-PCR (Brackets indicate that, considered as a group, patients or controls were signiﬁcantly different from basal conditions * p b 0.05, ** p b 0.01).
Results are presented relatively to basal culture condition value. Data are shown as mean ± SD excepted for panel A.
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stimulation of LPIN2 expression in the patient's and control's cells
(Fig. 6D). However, despite this up-regulation, lipin-2 was unable to
fully compensate for lipin-1 deﬁciency during inﬂammation as PAP1
activity remained unchanged.
3.9.2. Lipidmetabolism anomalies are enhanced upon inﬂammatory stimuli
TNFα + IL-1ß and to a lesser extent poly(I:C) treatments (Fig. 7B
and C) induced a massive accumulation of LDs and aggregated LDs in
the cytoplasm of the patient's myoblasts compared to basal condition
(Fig. 7A), with 98% of positive cells with TNFα + IL-1ß and 67% with
poly(I:C). LDs in control myoblasts were also increased after
TNFα + IL-1ß stimulation, but these LDs were of smaller size and less
abundant than in the patients' cells under the same condition (70% of
positive cells with TNFα + IL-1ß and 53% with poly(I:C)). Co-treatment
with anti-inﬂammatory agents such as cytokine inhibitors (Fig. 7D) and
the synthetic glucocorticoid dexamethasone (Fig. 7E and F) dramatically
decreased the number of LDs in the patients' myoblasts (85% decrease
with dexamethasone and 50% with the combined anti TNFα and
anakinra).
Total PL and TAG contents were determined in basal and pro-
inﬂammatory conditions. As shown in Table 1 and Fig. 3C, PL content
did not signiﬁcantly vary under TNFα + IL-1ß stimulation. In contrast,
the TAG content was signiﬁcantly higher in all myoblasts under pro-
inﬂammatory stress compared to basal conditions (Fig. 3D). When
reported to PL content, TAG content from P1, P3 and control increased
by 2.1, 1.5 and 2.6 fold respectively, compared to the basal condition.
The TAG increase was not associated with changes in the overall fatty
acid composition nor did it modify proliferation rate of myoblasts (data
not shown).
Altogether, these results show that cytokines and poly(I:C) drama-
tically alter lipid storage in myoblasts, particularly in the absence of
functional lipin-1.
Microarray analysis (see Tables S1 and S3), real-timePCRand immu-
noblot analysis (Fig. 4A and B) showed that the up-regulation of ACACBobserved in the patients' myotubes and myoblasts was not modiﬁed by
TNFα + IL-1ß treatment. By contrast, the malonyl-carnitine content of
the patients' myoblasts was further increased by TNFα + IL-1ß treat-
ment compared to controls (60.44 ± 4.89 vs 16.82 ± 1.19 pmol/mg
protein respectively, p b 0.01, Fig. 4C). Concomitantly, the CPT1 activity
in all patients'myoblastswasdecreased bypro-inﬂammatory treatment
while CPT1 activity increased in all controls' myoblasts (Fig. 4D). ATP
concentration which was lower in the patients' myoblasts compared
to controls in the basal condition further decreased after TNFα + IL-1ß
treatment in patient P1 and controls' myoblasts but not in patient P2
(Fig. S2).
3.9.3. Expression of known lipin-1 regulated genes and transcriptomic
studies in TNFα + IL-1ß condition
TNFα + IL-1ß treatment induced a sustained up-regulation of mRNA
levels of ACADVL and CPT2 in both patient's and control's myoblasts
(Fig. 8) while the expression of CPT1b and PPARδ was transiently stimu-
lated and PPARα was transiently slightly decreased. The expression of
PGC-1α was not signiﬁcantly modiﬁed although there was a trend for
up-regulation (Fig. 8).
Gene expression analyseswere also performed onmyotubes derived
from lipin-1-deﬁcient patients and controls subjected to TNFα + IL-1ß
stimulation for 24 h (Fig. S1A).
The set of genes regulated by the pro-inﬂammatory treatment
in both lipin-1-deﬁcient and control myotubes was largely similar
sharing numerous up-regulated (N300) and down-regulated (88)
genes (Fig. S1B and C, Tables S2 and S3). The majority of these
modulated genes belonged to the TNFα + IL-1β signaling path-
ways or were related to stress response (SOD2, metallothioneins),
indicating that the lipin-1-deﬁcient myotubes were able to build
an apparently normal inﬂammatory response. The set of inﬂammation-
modulated genes found in both controls' and patients' myotubes also
included genes encoding metabolic enzymes of energetic pathways (e.g.
glycolysis: PGK1, PGAM1, ENO2, PFKFB3, and GPD2) and lipid metabolism
(e.g.: APOL1, APOL3, FAPB5, and CH25H). Consistent with our quantitative
Fig. 7. Representative histological oil red O staining of myoblasts from patients (right panel, P3) and controls (left panel, C3). Culture conditions are indicated on the right. A: basal, B:
TNFα + IL-1β, C: PolyIC, D: TNFα + IL-1β combined with inhibitors of TNFα (ab9635) and IL-1β (anakinra), E: TNFα + IL-1β combined with Dexamethasone, F: Dexamethasone
(dex). Magniﬁcation 20x, the scale bar is shown in the right bottom panel. Similar results were obtained in several independent experiments.
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lower in the patients' myotubes compared to controls. Most of the genes
differentially expressed under basal culture conditionwere unaffected by
pro-inﬂammatory treatment (Table S2) excepted CAPN6, PIPOX, and
HOPX (increased) and CXCR4 (decreased). Finally a limited number of
genes displayed a differential induction speciﬁcally after TNFα + IL-1ß
(Table S3) among which very few are known to participate to the
immune response, again suggesting that the immune response is not
grossly affected in lipin-1-deﬁcient myotubes.
4. Discussion
Cellular lipid metabolism is regulated by a coordinated ﬁne-tuning
of lipogenesis (FA and TAG synthesis) and lipolysis (FAO activity).
Here we show that bothmetabolic pathways are altered in lipin-1-deﬁ-
cientmyoblasts, at least in part as a consequence of PAP1 deﬁciency and
increased ACACB expression [32], with subsequent LD and FFA accumu-
lation. Biochemical analyses and molecular biology experiments indi-
cated that basal lipid metabolism was not signiﬁcantly modiﬁed in
lipin-1-deﬁcient myoblasts apart from ACACB. Yet, lipid synthesis and
storage were profoundly affected as indicated by increased free fatty
acid content and accumulation of lipid droplets supporting our previous
proposition to classify LPIN1-dependent rhabdomyolysis as a novel form
of lipidmyopathy [20]. siRNA experiments further demonstrated the in-
verse relationships between LPIN1 or ACACB expression, CPT1 activity
and LD accumulation. Finally, pro-inﬂammatory stress induced by
TNFα + IL-1β or poly(I:C) exacerbated LD accumulation, decreased
CPT1 activity and increased triacylglycerol content, highlighting acrucial role of inﬂammation in the pathogenesis of lipin-1 deﬁciency. Al-
together these results support a role of inﬂammation as a potential trig-
gering factor of rhabdomyolysis.
LDs are formed by neutral lipids, mainly TAG and to a lesser extent
cholesterol esters, and are key storage compartments for the response
to increased energetic demand [33]. Their accumulation in LPIN1
mutated cells, mostly observed in inﬂammatory conditions, was
unexpected considering the major role of lipin-1 in TAG synthesis and
the importance of TAG synthesis in facilitating LD expansion [34].
Nevertheless, intracellular accumulation of lipids is a common feature
in lipin-1-deﬁcient models [35,36]. The up-regulation of lipin-2 in the
patients'myoblasts, also reported in the liver and heart from lipin-1-de-
ﬁcient mouse models [11,13,37], may account for the residual PAP1 ac-
tivity, allowing a limited synthesis of TAG. Furthermore, it was shown
that long-chain fatty acids display anunexpected high pKa value leading
to the hypothesis that FFA could accumulate in a cell mainly in an undis-
sociated form [38]. Accordingly, it is well known that lipids accumulate
mainly in the form of FFA and TAG in the oleaginous yeast Yarrowia
lipolytica [39]. Interestingly, in Y. lipolytica complete inhibition of FAO
leads to a large increase in FFA content resulting in larger LDs [40].
Since the neutral lipid fraction of the patient cells contains about 90%
FFA, we hypothesize that accumulated FFA could be stored in an inert,
non-toxic, form in the hydrophobic core of LD, togetherwith the neutral
lipids steryl esters and TAG. Indeed, the increase of TAG content in the
patient myoblasts induced by inﬂammatory conditions, is unlikely to
explain alone the large increase of LD number and size. Interestingly
lipin-1 is directly linked to LD biogenesis and expansion, as it catalyzes
a critical step of adipogenesis and colocalizeswith LDs in various species
Fig. 8. Time course analysis of selected Lipin-1 target genes mRNA expression in myoblasts stimulated with TNFα + IL-1β. Gene expression was measured by real-time RT-PCR and
normalized by POLR2A expression. Results are presented relatively to basal culture condition value. Data are shown as mean ± SD. The names of mRNA measured are indicated at the
top of each panel and time (hours) at the bottom. Brackets indicate that when considered as a group patients or controls were signiﬁcantly different from corresponding untreated
conditions (*: p b 0.05, ** p b 0.001). Samples follow the same order –C1, C2, C3, P1, P2, P3- in all panels. Results are shown as mean ± SD from three independent experiments.
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type” was strongly attenuated by anti-inﬂammatory agents such as
anti-TNFα and anti-IL-1β and to a higher extent by dexamethasone.
Such treatments might blunt or interfere with the cascade of events
leading to the dramatic skeletal muscle lysis in the patients and hence
may prove useful to prevent muscle lysis or reduce its severity. In this
view it is worth noting that corticoids are known to affect both lipogen-
esis and lipolysis and to induce ACACB and LPIN1 expression [43,44].
Lipin-1 is also themain isoform in the cardiacmuscle [7,21], a tissue
strongly dependent on FFA as energetic substrates. In contrast with
studies in mouse liver [11], Kok et al. [37] reported that although PAP1
activity was dramatically reduced in the heart of ﬂd mice, triglyceride
synthesis and FAO ﬂux appeared unaffected. However the measure of
FAO activity is known to have a limited sensitivity and may not detect
a moderate inhibition [45].
Altered transcriptional activity of lipin-1 may also contribute to the
phenotype of lipin-1-deﬁcient myoblasts. However, in contrast to the
liver, loss of lipin-1 expression did not change the expression of FAO
genes in the myotubes. Similarly, none of the target genes of PGC1a,
SREBP1 or NFATc4, the transcription factors or cofactors modulated by
lipin-1, was induced or repressed in our transcriptomic study with the
notable exception of ACACB [46]. It is possible that muscle
speciﬁc mechanisms compensate for lipin-1 deﬁciency or that thetranscriptional function of lipin-1 is less important for the expression
of these genes in the muscle cells. Nevertheless, the absence of obvious
metabolic and the limited transcriptional consequences of lipin-1 deﬁ-
ciency in normal culture conditions are in agreementwith the apparent
absence of symptoms between rhabdomyolysis episodes. Consistent
with the decreased heart function in ﬂd mice in vivo, we previously
reported gross alterations of the cardiacmusclewithmassive accumula-
tion of lipids in a patient who died during a rhabdomyolysis episode
[47], suggesting some heart metabolic dysfunction in this disease.
Clinicians should be aware that a defective heart function due to intra-
cardiac accumulation of lipids should be considered in this disease [48].
Because DAG, the product of PAP1 activity, is also the precursor of
several membrane phospholipids [49,50], altered cell membrane
composition and hence increased fragility or sensitivity to breakdown
injuries have been hypothesized [2]. However, skeletal muscle
and myoblast phospholipid contents appeared unchanged, and pro-
inﬂammatory stimuli did not signiﬁcantly affect phospholipid metabo-
lism in the myoblasts. Accordingly we did not observe gross alteration
in nuclear or ER morphology, nor apparent membrane remodeling.
Our results point to inﬂammation as a condition worsening pre-
existent alterations of lipid metabolism in lipin-1-deﬁcient myoblasts
and are consistent with its role as a trigger of the sudden rhabdomyolysis
episodes. Remarkably the expression of LPIN1 and genes involved in
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pro-inﬂammatory cytokines [51,52]. Indeed, the patients' myoblasts also
displayed a lower ATP content suggesting that the energetic metabolism
is decreased in basal culture condition despite our inability to demon-
strate signiﬁcant biochemical changes. This decrease was further en-
hanced by pro-inﬂammatory stimulation, supporting our hypothesis of
a triggering role of inﬂammation. Prolonged exercise and excess of circu-
lating FFAs also induce a mild state of inﬂammation. In these situations,
themuscles secrete various cytokines and chemokineswhichmay ampli-
fy immune response in a paracrine/autocrine fashion [53,54]. Notably, as
suggested by our transcriptomic study, these cytokines induce the mobi-
lization of endogenous fuel stores to maintain energy homeostasis
through transcriptional modulation of genes governing many aspects of
glucose and lipid metabolism [55], even if in our experiments major reg-
ulators such as PGC1α were not or barely modulated. In the other
way, lipin-1 regulates adipose tissue inﬂammatory response by
repressing transcriptional activity of the nuclear factor of activated T
cells c4 (NFATc4), which has an important role in the activation
of pro-inﬂammatory cytokine expression [10]. Suppression
of lipin-1 also increases expression and chemotactic activity of
monocyte chemoattractant protein-1 (MCP-1) which is involved
in monocyte/macrophage chemotaxis and adipose inﬂammation
in obesity [56], and in triggering LD biogenesis [57]. Both abilities
of lipin-1 to repress NFATc4 activity and MCP-1 activity may
inﬂuence macrophage recruitment to the fat tissue and inhibit
secretion of inﬂammatory factors. Interestingly, the excess of
ACACB has also been shown to increase pro-inﬂammatory cytokine
expression in the epithelial cells [58]. Inversely, we observed that the in-
ﬂammatory stress induced by TNFα and IL-1β in lipin-1-deﬁcient myo-
blasts did not further up-regulate ACACB expression, yet increased
malonyl-carnitine, used as a surrogate of malonyl-CoA, the product of
ACC2 activity. The phosphorylation state of ACC2 is known to regulate
its activity but couldnot bedetermineddue to technical issues and further
analyses are needed to understand the mechanisms underlying this
increase in response to pro-inﬂammatory stress speciﬁcally in lipin-1-
deﬁcient myoblasts. Altogether our results suggest that in basal condi-
tions lipin-1 deﬁciency results only in modest alteration of lipid metabo-
lism, consistent with the normal daily activities reported by the patients.
The up-regulation of lipin-2 suggests that compensatory mechanisms
may take place allowing a normal balance of lipogenesis and lipolysis.
Our results support a pathogenicmechanism of rhabdomyolysis episodes
triggered by inﬂammation, increasing lipid synthesis and affecting CPT1
activity and possibly FFA catabolism, thus translating in an imbalance
beyond adaptation capabilities. However the variability between patients
and theirmedical history suggests that inﬂammation is likely not the sole
possible trigger. In vitro IL6 release and expression of inﬂammatory re-
sponse genes were quite similar in patient and control myotubes and
myoblasts and, histological analysis ofmuscle biopsies of the patients out-
side of myolysis bouts repeatedly failed to reveal signs of chronic inﬂam-
mation such as macrophage inﬁltration. In this respect, lipin-2, which is
involved in the Majeed syndrome, an auto-inﬂammatory disorder with
recurrent fever [59], exhibits anti-inﬂammatory properties that control
TAG synthesis, JNK/AP-1 pathway activation and ultimately the up-
regulation of pro-inﬂammatory genes under palmitic stimulation [60].
Each lipin isoform might thus exert tissue-speciﬁc regulation of inﬂam-
matory pathways, underlining the potential critical role of inﬂammation
as a trigger of rhabdomyolysis. One may hypothesize that under normal
physiological conditions, the residual PAP1 activity, likely resulting from
compensation by lipin-2 up-regulation, would allow adequate lipid me-
tabolism to sustain normal muscle function and integrity. By contrast,
lipin-2 compensation would not be strong enough to support efﬁcient
adaptation to increased energetic demand, particularly with respect to
lipid catabolism induced by various inﬂammatory stresses.
In conclusion, we show that PAP1 activity is severely decreased in
lipin-1-deﬁcient muscle cells and is associated with ACACB up-regula-
tion, which may explain the accumulation of lipid droplets and freefatty acids in the patients' cells. Remarkably pro-inﬂammatory stress
increases lipid metabolism alterations, decreased CPT1 activity and ap-
pears to favor lipid synthesis and storage over oxidation. Thus, the path-
ogenic mechanism of lipin-1 rhabdomyolysis episodes would associate
genetic and environmental components, a combination likely to drive
acutemetabolic decompensation episodes in other inborn errors of me-
tabolism. Finally, anti-inﬂammatory agents may present interesting
therapeutic opportunities in the prevention of the devastating muscle
lysis episodes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.07.021.
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